Skip to main content

AI Bias Analysis

4 models · Takes ~15 seconds

MedPage Today

If It's COVID, Paxlovid? Studies Suggest a Rethink These Days

If It's COVID, Paxlovid? Studies Suggest a Rethink These Days
ShareXFacebook

(MedPage Today) -- Oral nirmatrelvir-ritonavir (Paxlovid) failed to spare COVID-19-vaccinated individuals from the worst outcomes if they got sick, though it may have helped speed recovery time and cut viral loads, according to two community-based...

M

Source

MedPage Today

Read full article at MedPage Today

Opens original article in a new tab

Advertisement

Related Health Stories

First Clinical Trial in MOGAD Meets Primary Endpoint
MedPage Today

First Clinical Trial in MOGAD Meets Primary Endpoint

(MedPage Today) -- The interleukin-6 (IL-6) inhibitor satralizumab (Enspryng) met its primary endpoint in the phase III METEOROID trial of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Satralizumab reduced the risk of...

Read more →
Advertisement